A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9

Soo-You Lee, June Soo Kim, and Jong-Won Kim

Departments of Laboratory Medicine and Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient heterozygous for the CYP2C9*3 allele. A 30-year-old woman with an artificial cardiac pacemaker was taking warfarin to prevent thromboembolism. This patient had an extremely elevated international normalized ratio (INR) of prothrombin time (PT) following standard doses of warfarin and experienced difficulties during the induction of anticoagulation. Genotyping for CYP2C9 revealed that this patient was an intermediate metabolizer with genotype CYP2C9*1/*3. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

Key Words: Warfarin, cytochrome P-450 CYP2C9, polymorphism, prothrombin time, pharmacogenetics

INTRODUCTION

Warfarin, a widely used anticoagulant, may increase the risk of bleeding complications with narrow therapeutic index.1-3 The prolongation of the prothrombin time (PT) remains the primary way to measure the anticoagulant effect of warfarin. Because warfarin is subject to great variability between individuals in its pharmacokinetics with effective daily doses ranging from 0.5 mg to 60 mg,4 therapy should be individualized by monitoring patient's international normalized ratio (INR) of PT.

Warfarin metabolism is catalyzed by CYP2C9, which metabolizes S-warfarin to inactive S-7-hydroxywarfarin.5 A genetic polymorphism of CYP2C9 contributes to variability among patients for required maintenance doses of warfarin. Multiple studies have clearly demonstrated an increased frequency of CYP2C9 allelic variants such as CYP2C9*2 and CYP2C9*3 in patients stabilized on low-dose warfarin therapy and have established relations between genetic deficiency in CYP2C9 enzyme activity with increased likelihood of extremely elevated INRs and major bleeding events, compared with the general population.6-11

In this report, we present a case of warfarin therapy in a patient with the variant CYP2C9*1/*3, which resulted in decreased activity of CYP2C9. Extremely prolonged PT during the induction phase of standard warfarin therapy was found and a reduction of warfarin dosage was required to get the target INR in this case.

CASE REPORT

A 30-year-old woman with an artificial cardiac pacemaker presented to the clinic complaining of dizziness and dyspnea. The patient had a history of hypertrophic cardiomyopathy with complete atioventricular block and the pacemaker had been implanted in her 13 years before presentation. Her prescription medication for the previous 2 years included lasix 20 mg, spironolactone 12.5 mg, midampril 2.5 mg, and teprenone 50 mg twice a day.

She had suffered from dizziness and dyspnea...
for the last 2 months and visited the outpatient clinic. Physical examination of this woman showed a blood pressure of 110/68 mmHg, a heart rate of 76 beats/min, and normal body temperature. Her body weight was 45.2 kg and she was 156 cm in height. Initial laboratory results were unremarkable with a normal PT of 13.5 sec (INR 1.03). Cardiomegaly was found on chest X-ray. Echocardiogram indicated atrial fibrillation. Echocardiogram also revealed decreased systolic function and hypertrophy of the left ventricle. The patient was started on 4 mg of warfarin daily to prevent thromboembolism.

When she revisited the outpatient clinic after 1 week, her PT was found to be 88.2 sec (INR 6.36) (Fig. 1). On admission to the ward, 10 mg of Vitamin K was injected with warfarin withdrawal. After normalization of the patient's PT, 2 mg/day of warfarin was initially prescribed and the dose was then increased to 3 mg/day, which resulted in a PT of 36.3-47.0 sec (INR 2.69-3.45). Administration of warfarin doses was reduced even further (1-2 mg/day) to achieve the target therapeutic INR of 2.0 to 3.0 and she was discharged after 16 days of hospitalization. She continues to receive warfarin therapy at the outpatient clinic monthly and her PT remains stable, even though her warfarin dose has been reduced to 2 mg/day.

This patient was genotyped for CYP2C9. DNA was isolated from peripheral blood and all 9 exons of CYP2C9 gene were amplified by PCR. The PCR products were sequenced using ABI PRISM BigDye terminator Cycle sequencing kit (Perkin-Elmer, USA) and an ABI Prism 3100 Genetic Analyzer (Perkin-Elmer, USA). The patient was an intermediate metabolizer with the genotype of CYP2C9*1/*3 (Fig. 2).

**DISCUSSION**

CYP2C9, one of the major isoforms of the CYP2C subfamily, is involved in the metabolism of many clinically important therapeutic agents such as warfarin, phenytoin, sulfonylurea and nonsteroidal anti-inflammatory drugs. Genetic polymorphisms of CYP2C9 bring about significant variability among individuals in drug response. At the time of this report, variant alleles of CYP2C9 had been reported. Previous studies have demonstrated that 2 common variants CYP2C9*2 and CYP2C9*3 are associated with reduced catalytic activity of CYP2C9. Therefore, subjects who are homo- or heterozygous for these variant alleles require reduced maintenance doses for CYP2C9 substrates including warfarin. The CYP2C9*3 variant would have a greater impact than the CYP2C9*2 variant on the dose requirements of warfarin. Intermediate metabolizers with heterozygous CYP2C9*2 and CYP2C9*3 would require on average 21% and 34% lower maintenance doses of warfarin, as compared with extensive metabolizers (CYP2C9*1/*1). Poor metabolizers with 2 variant alleles (CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3) would require 60-90% lower doses of warfarin than extensive metabolizers.

Allele frequencies of CYP2C9 variants have been shown to be markedly different among populations. Caucasians possess higher frequencies of CYP2C9*3 than Asians (6-10% vs 2-5%). There have been no documented Asian carriers of the CYP2C9*2 variant, while 8-20% of Caucasians appear to have the CYP2C9*2 allele.
Yoon et al reported that from a pool of 574 Koreans 2.3% were heterozygous for CYP2C9*3 and none were found to be carriers of CYP2C9*2. Interethnic difference in the prevalence of CYP2C9 variants causes an apparent need for an interethnic difference in the maintenance dose of warfarin.

There are several Korean reports regarding warfarin dosing and its toxicity based on clinical assessment and PT monitoring. This case study is the first clinical report of a Korean patient with the CYP2C9*1/*3 genotype as the major determinant of warfarin intolerance. She attained an extremely high INR at the standard doses and might be at a higher risk for developing severe complications. In this patient, we could not identify any specific pharmacokinetic or pharmacodynamic factors associated with warfarin response, such as drug interactions or disease conditions. Therefore, a pharmacogenetic test was performed to explore the possible genetic factors contributing to the unusual drug response. This patient could have taken appropriate therapeutic changes earlier and been maintained on a safer regimen with lower doses, if she had been genotyped at the beginning of warfarin therapy.

The CYP2C9 genotype is associated with a risk of over-anticoagulation and bleeding complications. Previous studies have suggested that the variant group, compared with patients with the wild-type genotype, required a higher rate of above-range INR, more time to therapeutic INR, larger maintenance doses, more time to stable warfarin dosing, longer hospitalization, and a higher risk of serious bleeding events.

At present, clinicians are used to adjusting the warfarin dose based on PT and clinical response. Additional CYP2C9 genotyping can serve as an important guide for more rapid dosage adjustment and prediction of drug response in each individual. CYP2C9 genotyping is recommended to complement PT monitoring especially when the unusual metabolic capacity of warfarin is suspected. Characterization of CYP2C9 polymorphic alleles may identify patients at risk, so that warfarin can be given more cautiously, especially during the induction phase of anticoagulation.

REFERENCES

1. Miners JO, Birkett DJ. Cytochrome P450C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
2. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003;3:202-14.
3. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603.
4. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1997;353:717-9.
5. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
6. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003;13:247-52.
7. Higahi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FL, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.
8. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002;194:267-73.
9. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-28.
10. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702-10.
11. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63.
12. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-39.
13. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997;7:51-8.
14. Ingelman-Sunberg M, Nebert DW, Daly AK. Human cytochrome P450 P450 genes. Available from: URL: http://www.imm.ki.se/CYPalleles/cyp2c9.htm
15. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001;51:277-80.
16. Lee HC, Cho SY, Lee HJ, Kim CJ, Park JS, Chi JG. Warfarin-associated fetal intracranial hemorrhage: a
17. Huh SH, Kim DI, Kim ES, Lee BB, Moon JY, Joh JH. Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb. Yonsei Med J 2003;44:686-93.

18. Lee JH, Park JS, Chung SW, Sohn DK, Kim SH, Lee HS. Warfarin toxicity patients in the emergency department. J Korean Soc Emerg Med 2003;14:145-9.